Company intelligence / Profile preview
Medeor Therapeutics
South San Francisco, California, United Statesmedeortx.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Medeor completed a pivotal Phase 3 trial with its lead product candidate MDR‑101, a single-dose cellular therapy derived from a living kidney donor’s blood. The study exceeded its target success rate—patients achieved functional immune tolerance and were able to discontinue all immunosuppressive drugs without graft loss or acute rejection. Results are under peer review. Operations have been suspended pending acquisition to complete the BLA filing.[1][4]
- Therapeutic areas
- HematologyImmunologyNephrology
- Modalities
- Cellular immunotherapyHematopoietic stem cell therapy[7]
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Medeor Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Medeor Therapeutics.